1. Home
  2. PBT vs ERAS Comparison

PBT vs ERAS Comparison

Compare PBT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Permian Basin Royalty Trust

PBT

Permian Basin Royalty Trust

HOLD

Current Price

$17.60

Market Cap

920.1M

Sector

Energy

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$3.57

Market Cap

927.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PBT
ERAS
Founded
1980
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
920.1M
927.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PBT
ERAS
Price
$17.60
$3.57
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$3.71
AVG Volume (30 Days)
87.7K
2.0M
Earning Date
01-01-0001
11-12-2025
Dividend Yield
1.88%
N/A
EPS Growth
N/A
N/A
EPS
0.33
N/A
Revenue
$17,266,423.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$53.84
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.01
$1.01
52 Week High
$20.46
$3.62

Technical Indicators

Market Signals
Indicator
PBT
ERAS
Relative Strength Index (RSI) 42.12 71.90
Support Level $17.13 $3.15
Resistance Level $18.73 $3.48
Average True Range (ATR) 0.77 0.22
MACD -0.08 0.03
Stochastic Oscillator 17.86 99.81

Price Performance

Historical Comparison
PBT
ERAS

About PBT Permian Basin Royalty Trust

Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Share on Social Networks: